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Abstract
Background: Many different genetic alterations are observed in cancer cells. Individual cancer genes display point
mutations such as base changes, insertions and deletions that initiate and promote cancer growth and spread. Somatic
hypermutation is a powerful mechanism for generation of different mutations. It was shown previously that somatic
hypermutability of proto-oncogenes can induce development of lymphomas.
Methodology/Principal Findings: We found an exceptionally high incidence of single-base mutations in the tumor
suppressor genes RASSF1 and RBSP3 (CTDSPL) both located in 3p21.3 regions, LUCA and AP20 respectively. These regions
contain clusters of tumor suppressor genes involved in multiple cancer types such as lung, kidney, breast, cervical, head and
neck, nasopharyngeal, prostate and other carcinomas. Altogether in 144 sequenced RASSF1A clones (exons 1–2), 129
mutations were detected (mutation frequency, MF=0.23 per 100 bp) and in 98 clones of exons 3–5 we found 146
mutations (MF=0.29). In 85 sequenced RBSP3 clones, 89 mutations were found (MF=0.10). The mutations were not
cytidine-specific, as would be expected from alterations generated by AID/APOBEC family enzymes, and appeared de novo
during cell proliferation. They diminished the ability of corresponding transgenes to suppress cell and tumor growth
implying a loss of function. These high levels of somatic mutations were found both in cancer biopsies and cancer cell lines.
Conclusions/Significance: This is the first report of high frequencies of somatic mutations in RASSF1 and RBSP3 in different
cancers suggesting it may underlay the mutator phenotype of cancer. Somatic hypermutations in tumor suppressor genes
involved in major human malignancies offer a novel insight in cancer development, progression and spread.
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Introduction
We have performed a comprehensive deletion survey of 3p on
more than 400 of lung, renal, breast, cervical and ovarian
carcinomas (major epithelial cancers) using a defined set of markers,
combining conventional LOH with quantitative real-time PCR
(QPCR), comparative genomic and NotI microarrays hybridisa-
tions [1,2,3,4,5]. We identified two most frequently affected 3p21.3
regions, LUCA (LUng CAncer) at the centromeric and AP20 at the
telomeric border of 3p21.3. Aberrations of either region were
detected in more than 90% of the studied tumors suggesting they
harbor multiple tumor suppressor genes (TSG) [5,6,7].
One of them is RASSF1 gene (from LUCA region) that can exist
in different alternative splicing forms (at least 7 different isoforms).
In this work we studied the most important RASSF1A, the largest
splicing form [8]. Several studies have shown that loss of RASSF1A
expression occurs because of tumor acquired promoter DNA
methylation in many different cancers. For example, RASSF1A is
silenced by promoter hypermethylation in over 90% of small cell
lung carcinomas (SCLC) and clear cell renal cell carcinomas
PLoS ONE | www.plosone.org 1 May 2009 | Volume 4 | Issue 5 | e5231(RCC) and in about 40% of non-small cell lung carcinomas
(NSCLC). The gene is able to suppress growth of lung and renal
cancer cells in culture and tumor formation in mice [6]. In
addition, occasional missense mutations in RASSF1A have been
reported. RASSF1A codes for 340 amino acids. The amino acid
sequence of RASSF1A contains a predicted diacylglycerol (DAG)
binding domain and a Ras association domain. RASSF1A can
induce cell-cycle arrest by engaging the Rb-family cell cycle
checkpoint [9]. These and other results strongly suggest that
RASSF1A is an important human tumor suppressor protein acting
at different levels of tumor progression [6].
Another gene is RBSP3 also called HYA22 and CTDSPL. It exists
in two splice forms (A, 265 amino acids and B, 276 amino acids)
that map to AP20 region and belongs to a gene family of small C-
terminal domain phosphatases that may control the RNA
polymerase II transcription machinery [10]. Expression of the
gene was greatly decreased in several SCLC and NSCLC cell
lines. RBSP3 showed growth suppression with regulated transgenes
in culture and suppression of tumor formation in SCID mice. It
was demonstrated that transient expression of both A and B forms
resulted in drastic reduction of phosphorylated form of RB protein
presumably leading to a block of the cell cycle at the G1/S
boundary. After this finding the gene was renamed (RB protein
serine phosphatase from chromosome 3). All these features are
consistent with classical characteristics of a TSG.
Interestingly, both RASSF1 and RBSP3 could collaborate in cell
cycle arrest: the former by inhibiting cyclin D1 [9] and the latter
by dephosphorylating RB [10]. This supports the hypothesis that
TSGs in these two regions could act synergistically [4,5].
Moreover two other TSGs from these regions could cause
increasing mutation frequencies in tumors (MLH1 from AP20
and G21/NPRL2 from LUCA) [11,12,13].
It is well known that cancer is the result of genetic and
epigenetic changes and point mutations is one of the most
important mechanisms for the development of cancer [14,15].
Previously, others and we detected numerous single-base
changes/mutations in RASSF1A that were believed to be SNPs
[8,16,17]. Moreover, RBSP3 mutations were detected in all 14
tumors of different origins expressing the gene [10].
To study the apparently high mutation frequencies of TSG(s) in
these regions of 3p21.3, we performed a comprehensive mutation
analysis of RASSF1A [18,19] and RBSP3/HYA22 [10] in several
cancers. Here we show that exceptionally frequent single-base
mutations occur in these genes in multiple cancer types. The
mutations were not cytidine-specific as would be expected if
generated by AID [20] or other APOBEC family [21,22] enzymes.
These mutations were not due to RNA editing and appeared de
novo during cell divisions.
Results
Bioinformatics analysis of EST cDNA clones reveals high
mutation frequency of RASSF1 and RBSP3
First we examined publicly available EST sequence data for
RASSF1A and RBSP3 (for RASSF1A Accession No. NM_007182;
RBSP3A, Accession No. AJ575644, and for RBSP3B, Accession
No. AJ575645). Sequences with homology below the threshold
(see Materials and Methods) i.e. containing multiple distinct
mismatches to the annotated genes and unknown nucleotides (N)
were not considered. Sequences close to the end of reads were also
excluded. The data presented in Table 1 show that the RASSF1A
and RBSP3 genes were mutated at extremely high rates. For the
RASSF1A we considered only 17 clones (mutation frequency per
100 bp, MF=0.22). Six of them were obtained from cancer tissues
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sequences were from normal tissues (four clones with one
mutation) and MF=0.1, i.e. mutation frequencies were statistically
significantly different (P=0.025).
Eighty one per cent of the RBSP3 sequences (63 out of 79)
contained mutations/mismatches. MF for RBSP3 ESTs was 0.63.
Againitwas muchhigherinclonesisolated from cancer(MF=1.05)
than from normal tissues (MF=0.45). This difference was also
significant (P,0.001). The difference was even more pronounced
for mutations changing amino acid sequences (MF 0.72 versus 0.24)
and similar for RASSF1A clones (MF 0.33 versus 0.1).
The number of available (and mutated) EST sequences was
significantly higher for both RASSF1A and RBSP3, but due to the
very stringent criteria many were excluded from analysis.
Importantly, we have also detected hypermutations in other
exons of RASSF1A, shared with RASSF1C (recently shown to be a
TSG with a different tissue specificity than RASSF1A, see [23]. MF
for the exons 3–6 was 0.43 and for the mutations changing amino
acids MF=0.25 and therefore RASSF1C is also hypermutated.
A similar bioinformatic analysis was done for the insulin gene
(333 bp, complete ORF). No mutations were detected in more
than 1000 sequenced clones isolated from cell lines and somatic
tissues. In 20 available p16/INK4a (exons 1–3, 447 bp) clones
sequenced from cancer and normal cells we found no mutations
and in 6 clones for GPR14 (1170 bp) only 1 mutation was found in
cancer cells (MF=0.01). In our experiments described below (see
next Section and Section ‘‘Different mutations frequencies in other
genes’’) in 31 sequenced GPR14 clones no mutations were found
indicating that this mutation is rather rare. The mutation
frequency for GPR14 was statistically significantly different as
compared both to the RASSF1A and RBSP3 (P=0.01).
Frequent mutations in RASSF1A in human carcinomas,
cancer and haematopoietic cell lines
During analysis of RASSF1A we have isolated several mutant
clones including one double mutant [16]. This high frequency of
mutations was surprising since for RASSF1A and other candidate
genes in the AP20 and LUCA regions the mutation frequencies
were reported to be low to none [6,19]. At the same time many
polymorphisms were recorded for RASSF1A and in many cases it
was not clear whether it was a real single nucleotide polymorphism
or somatic mutation in cancer cells because control normal cells
were not available [8]. Importantly, in all these studies single-strand
conformation polymorphism (SSCP) and direct sequencing from
PCR products was used. The admixture of stroma, blood vessels,
lymphocytes and other normal cells would hamper detection of
mutations using these methods (see M/M). Tumor heterogeneity
creates additional problems for recognizing mutations. Therefore
we decided to re-investigate the mutational status of RASSF1A in
multiple tumor types including primary tumors and cancer cell
lines. First, RASSF1A cDNA was isolated from an RCC biopsy
(T356) and the surrounding normally looking kidney parenchyma
(N356). Several cDNA clones were sequenced. In six clones derived
from normal kidney parenchyma, no mutations were found.
However of seven clones from the tumor tissue, mutations were
detected in three (P=0.14). All were A to G substitutions. To
exclude RNA editing, genomic DNA from the same patient was
isolated and the first two exons (DAG domain) of RASSF1A were
amplified by PCR. Several clones derived from normal and tumor
tissue were then sequenced: all six clones from the tumor biopsy
showed mutations while of the fourteen analyzed clones from
normal tissue only one was mutated (P,0.001). The observed
mutations in the cDNA from tumor cells were not created by RNA
editing because the mutations were detected also on genomic DNA
level. Normal cell contamination and high expression of RASSF1A
in normal cells, compared to cancer cells, can explain the different
ratios between mutated and normal RASSF1A clones from cDNA
and genomic DNA. Most surprising was the fact that with the
exception of two genomic clones from the tumor biopsy with
deletion of C at position 254 (Accession No. NM_007182), all other
detected mutations were in different positions.
As a control we amplified GPR14 from the same patient and
sequenced 10 clones from cancer and from the surrounding
normal tissue. No mutations were found proving that high
mutation rate is specific for the RASSF1A gene.
To check whether different mutations in the same tumor
occurred due to the tumor heterogeneity or some other
mechanism(s), we isolated and sequenced RASSF1A clones (only
exon 1 and 2; 391 bp) from genomic DNA of four RCC cell lines.
In TK164 all three and in KRC/Y (2+2) all four sequenced clones
contained mutations. In TK10, among 22 clones, 9 were mutated.
Importantly, the majority of clones contained different mutations.
Only one clone was sequenced from Caki1, and it was mutated.
We also sequenced this gene from genomic DNA of four
lymphoid cell lines (BL2 and RAMOS are Burkitt cell lines, and
IARC171 and MutuIII are lymphoblastoid cell lines) and the
results were very similar to the RCC cell lines (Table 2).
Altogether, among 84 sequenced clones 55 contained mutations
that in most cases differed. MF in RASSF1A in these experiments
was between 0.14 and 0.70.
In all further experiments, we analyzed genomic DNA (exon 1
and 2 for RASSF1A and the whole RBSP3 transgene in pETE
vector) if not specially mentioned.
Mutations in RASSF1A can be generated de novo
To distinguish between the possibility that different mutated
RASSF1A genes were mutated at once (‘‘burst of mutations’’) or
were constantly generated over time, we performed experiments
with single cells. In this experiment BL2 cells, (which previously
showed the highest rate of mutation: 10 clones with 25 mutations),
were diluted and plated into wells with an expected frequency of
0.3 cells per well. Three randomly selected wells (designated as
BL2-cl.1, 2 and 3) containing single cells were expanded and
further analyzed. DNA was isolated from these clones after 10
days (approximately 10 divisions, 10
3 cells).
The results were as follows: for BL2-cl.1, five of 10 sequenced
clones were mutated (mutation frequency per 100 bp (MF), was
0.14), for BL2-cl.2, five of 13 clones (MF=0.15; two clones
contained T43T mutations with codon changed from ACA to
ACG) and for BL2-cl.3, three of 17 clones were mutated
(MF=0.07; two clones contained N70G mutations). Altogether
16 single base pair mutations were detected, all were transitions
and only five of them showed mutated G or C. This experiment
clearly shows that mutations in the RASSF1A locus could be
generated de novo during cell proliferation.
The complete list of 129 mutations (111 mutations were
different) found in exons 1 and 2 of RASSF1A in all experiments is
shown in Table S1A. See also Table 2 and 3 and Figure 1A.
Altogether 144 clones were sequenced (56,3 KB) and the average
frequency of mutations was 0.23/100 bp for transcribed sequences
and 0.17/100 bp for coding sequences. Among them, there were
four nucleotide changes that occurred in non-coding 59, three stop
(nonsense) and five frameshift (deletions) mutations. Of the
remaining 127 mutations, 82 were missense and 35 synonymous.
RBSP3 is also hypermutated in various cancers
During previous analyses of small cell lung carcinoma (SCLC)
cell line N417, two RCC, one breast carcinoma (BC) and two
RASSF1, RBSP3 High Mutability
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detected mutations in the RBSP3 cDNA in all six cases [10; see
Table S2A].
To test whether the hypermutation feature is a characteristic
only of the RASSF1A gene or a more general phenomenon, we
similarly analyzed the recently identified multiple tumor suppres-
sor gene RBSP3 located in AP20, 3p21.3 telomeric region [10].
Using RT-PCR, cDNA was isolated from two of each RCC, BC
and OC biopsies and the SCLC cell line N417. Multiple clones
were sequenced. Results, presented in Table S2A, Table 3 and
Figure 1B, showed that almost all isolated clones suffered
mutations. As reverse transcriptase used in RT-PCR has a
significantly higher error rate than other polymerases used in
PCR, we attempted to reproduce the observed high mutation rate
at the genomic DNA level, as in the case with RASSF1A.
Unfortunately, it was difficult to perform this experiment on the
genomic RBSP3 due to the large size of the gene (more than
120 kb), numerous small exons (at least 9), and high GC content
(reaching 100% in some regions). However this problem was
solved using cloned RBSP3 in SCID mice.
RBSP3 revealed high mutability in SCID mice on genomic
level
SCLC cell line ACC-LC5 and RCC cell line KRC/Y were
transfected with RBSP3A and RBSP3B splicing isoforms in the
pETE vector and stable cell clones were isolated. Four of these
clones (AHA1 and AHB1 for ACC-LC5 and KHA4 and KHB9
for KRC/Y) were inoculated into SCID mice (see M/M).
Cell clones KHA4 and KHB9, containing RBSP3A or RBSP3B
were grown in vitro in parallel with tumors in SCID mice. After 8
weeks DNA was isolated from grown tumors and cell lines, and the
RBSP3A and B genes were amplified by PCR from pETE vector
and cloned. Again multiple clones were sequenced and results of
the experiment are shown in Table 4 and Table S2B. Only 30% of
RBSP3 KHA4 and KHB9 plasmid clones were mutated in vitro,a s
compared to 85% mutated clones after growth in SCID mice. This
difference according to Fischer test is statistically significant
(P,0.001).
In summary, in RBSP3 experiments we identified 89 mutations
among which 79 were individually distinct (see Tables S2A and
S2B). The average frequency of mutations was 0.10/100 bp for
transcribed sequences. This frequency is more than 0.11/100 bp
for coding sequences (see Table 3 and Figure 1B). Among them,
seven nucleotide changes occurred in non-coding regions and five
were frameshift (deletions) mutations. Of the remaining 77
mutations, 68 were missense and 9 synonymous.
Thus, the mutation frequency was 2.5 fold less than for the first
two exons of the RASSF1A (see above). The significant difference in
mutation frequencies could be accounted for by differences in
nucleotide composition of the genes, or it could reflect intrinsic
differences in the hypermutation rates of the genes. It could also be
important that for the RBSP3 the whole gene was sequenced while
for the RASSF1A only its 59 end.
RASSF1A and RBSP3 amplified by PCR from E.coli DNA
don’t show high frequency of mutations
We have performed PCR amplification of E. coli DNA
containing plasmids (i.e. total DNA isolated from E.coli containing
mixture of genomic and plasmid DNA) with these two genes. For
each gene ten and four ng of DNA was used. Unfortunately lower
Table 2. Mutations in RASSF1A exon 1and 2 in different cell types.
Locus
RASSF1A/Cell
line Description
Number of
clones, mutated+
nonmutated
Mutation
frequency,
per 100 bp
Total
number of
mutations Deletions
Transitions
over
transversions
Mutations
of G/C
nucleotides
IARC171 Burkitt’s lymphoma derived cell line 11+7 0.23 15 no 2 9
BL2 Burkitt’s lymphoma derived cell line 10+0 0.70 25 3 1 16
RAMOS Burkitt’s lymphoma derived cell line 11+2 0.56 26 1 1.2 15
mutuIII Burkitt’s lymphoma derived cell line 7+0 0.56 14 1 1.6 9
TK10 renal cell carcinoma derived cell line 9+13 0.15 12 no 0 8
TK164 renal cell carcinoma derived cell line 3+0 0.28 3 no 2 2
KRC/Y renal cell carcinoma derived cell line 2+2 0.14 2 no 0 no
T356(RCC) renal cell carcinoma biopsy 6+0 0.51 11 3 0.6 5
N356(RCC) normal renal cell biopsy 1+13 0.02 1 no 0 no
Caki1 renal cell carcinoma derived cell line 1+0 0.28 1 no 0 1
doi:10.1371/journal.pone.0005231.t002
Table 3. Experimental mutations frequency in the RASSF1A and RBSP3 genes.
Gene, length
Number of sequenced
clones
Total length/coding
sequences, Kbp Number of mutations
Mutation frequency, per
100 bp
total In coding region total In coding region
RASSF1, exons 1–2 144 56.3/51.4 129 89 0.23 0.17
RASSF1, exons 3–5 98 50.6 146 145 0.29 0.29
RBSP3, exons 1–8 85 85.3/70.6 89 79 0.10 0.11
doi:10.1371/journal.pone.0005231.t003
RASSF1, RBSP3 High Mutability
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products for further cloning. Ten clones in each experiment were
sequenced and no mutations were detected. These results indicate
that the observed hypermutation rate of RASSF1A and RBSP3
cannot be explained by PCR polymerase errors.
Search for founder mutations in RASSF1A in single cell
clones
The main idea of this experiment was the following. If a
mutation originates in the cell and not in the tube in vitro then in
the cell population grown from one cell some fraction (depending
on the number of alleles present in the single cell) of plasmid clones
should contain the same (i.e. a founder) mutation. To perform this
experiment we isolated 15 single cell KRC/Y clones as described
in the section ‘‘Mutations generated de novo’’. In this case we grew
the cells for three weeks to obtain more DNA and generate more
mutated clones. KRC/Y cells were used instead of BL2 cells as it
was easier to detect that we have one cell in the well. However, we
of course cannot exclude that in some of the 15 selected wells there
were more than one cell. RASSF1A exons 3–5 were tested in this
experiment (see M/M) as they were more easily isolated than
exons 1 and 2 and contained more sequence information (516 nt
vs. 391 nt). Moreover, according to EST sequence data this part of
RASSF1A has higher MF. From each PCR reaction 10 plasmid
clones were selected and DNA was isolated. However, due to
different technical problems (no or rearranged insert, bad quality
DNA or sequencing, etc.) usually only six-seven plasmid clones
were further analysed. Totally 98 plasmid clones were sequenced
(Table 5). One founder mutation was detected in all cell clones and
in 46 (47%) of plasmid clones. It was a change of A to G (nt26735,
Accession No. AC002481) just at the border of intron 2 and exon
3. This mutation destroyed the splice acceptor site AG/G and thus
inactivated the gene. As this founder mutation appeared in all
single cell clones most probably it originated before we started to
do this experiment. Forty other founder mutations specific for
each cell clone were also detected (see Table 5 and Table S1B).
Interestingly in one case it was possible to construct a tree showing
how founder mutations were accumulated. First it was only one
mutation than two and then additional independent mutations
(Figure 2).
Figure 1. Mutations in RASSF1A and RBSP3 in natural and experimental tumors. Position of mutations detected in RASSF1A and RBSP3 is
shown in A and B respectively. Examples of mutations are shown in C. For RASSF1A only mutations in coding sequences of exons 1 and 2 are shown.
Mutations in the whole coding part of RBSP3 are shown. Red ‘‘X’’ marks stop nonsense mutations or deletions. ‘‘Z’’ designates synonymous
mutations.
doi:10.1371/journal.pone.0005231.g001
Table 4. Mutation frequency of the RBSP3A and RBSP3B
genes in vitro and in vivo in the gene inactivation test.
Gene/cell clone In vitro In vivo
tested mutated tested mutated
RBSP3A/KHA4 11 3 13 10
RBSP3B/KHB9 12 4 15 14
Total 23 7 28 24
doi:10.1371/journal.pone.0005231.t004
RASSF1, RBSP3 High Mutability
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Similar sequencing experiments were performed with insulin
and albumin genes isolated from KRC/Y cell line (see M/M). In
contrast to RASSF1A and RBSP3 results, only one of 21 sequenced
insulin genomic clones (999 bp including complete ORF) and one
of 19 albumin cDNA clones (700 bp, exons 12–15) were mutated
(MF for both genes was less than 0.01). However in both cases, we
could not exclude the possibility of polymorphisms. Additionally,
two more genes were tested for mutations in genomic DNA.
GPR14 (G protein-coupled receptor 14, 1018 bp) and transcrip-
tion elongation factor A (SII) TCEA1 (1066 bp) were PCR
amplified (see M/M) from DNA of KRC/Y cells and 11 clones
for each gene were sequenced. All clones contained normal copies
of the gene. No mutations were found in other 3p21.3 candidate
genes: BLU (15 clones were sequenced), 101F6 (6 clones), PL6 (6
clones) after KRC/Y stable clones containing these genes were
inoculated into SCID mice. Moreover, for already mutated
mutFUS1 (10 clones) and mutP53 (6 clones) no additional
mutations were found (data not shown).
Mutations in RASSF1A, RBSP3A and RBSP3B are not
generated by AID or APOBEC related mechanisms
It has been recently shown that the activation-induced cytidine
deaminase (AID) is responsible for somatic hypermutations in
activated B cells. Moreover hypermutations generated by this
enzyme in oncogenes can cause malignancies in haematopoietic
cells [24]. Although much remains to be learned concerning AID,
several target sequence motifs for the mutations have been
identified, namely WRC, RGYW and DGYW causing C/G
mutations. The large family of APOBEC genes, also shown
recently to mutate genes on DNA level [21,22], mostly targeted
the RCW motifs causing mutations in C/G. Therefore, we
checked whether these motifs were targeted or more frequent in
RASSF1 and RBSP3 sequences when compared to the stable
insulin gene. The frequency of the WRC motif per 100 bp varies
from 12.3 to 14.3 for RASSF1 and RBSP3 genes, and the insulin
gene contains 16.5 such motifs per 100 bp. Other motifs showed
the same distribution (also higher in the insulin gene), arguing
against the involvement of these enzymes in hypermutating the
RASSF1 and RBSP3 genes described here. Indeed, the APOBEC
and AID enzymes cause mutations almost exclusively in C/G
nucleotides, while we observed mutations of all 4 nucleotides
(Figure 3). The results actually showed that mutations in A/T were
even more frequent than in C/G. We tried to find a recognition
motif. We studied all mutations (Figure 3A) or a subset of
mutations (Figures 3B and 3C), but no obvious motifs have been
yet identified.
More studies are needed to resolve this question as this pattern
can be different in normal and cancer cells and could be
dependent on nucleotide composition of a gene. These small
differences in patterns could mask the recognition motif.
RASSF1A and RBSP3 mutants from RCC biopsy and lung
cancer cell line have significantly reduced growth-
inhibiting activity
We tested one RASSF1A gene, isolated from an RCC biopsy
that contained two mutations (Cys65Arg and Val211Ala), for
growth inhibition under cell culture conditions following transfec-
tion into the KRC/Y and prostate cancer LNCaP cells. In KRC/
Y cells the mutated gene had a significantly reduced growth
suppression activity (Figure 4A) while in LNCaP it had almost no
suppressing activity (same as the empty vector, see [16,17]).
In another experiment, we used RBSP3 clones isolated from
N417 SCLC cell line with a His139Tyr mutation. Again
significant decrease in growth suppressor activity was observed
(Figure 4B).Clearly, not all mutations found in this study would
inactivate the RBSP3 and RASSF1 genes, and this may be
especially true for mutants isolated from normal cells some of
which could be polymorphisms. Indeed, different mutants of
RBSP3 had significantly different growth suppression activity
(Figure 4B).
Conclusions
By sequencing 327 RASSF1A and RBSP3 clones, we detected
364 mutations with frequencies reaching 0.70 per 100 bp.
Interestingly many clones contained more than 1 mutations (see
Table S3A, B, C). Only one SNP was detected in RASSF1A ten
clones (exon1a – AAGRCAG, K21Q) and it was excluded from
the list of mutations [http://www.ncbi.nlm.nih.gov/SNP/snp_ref.
cgi?locusId=11186]. No SNP were found in RBSP3 sequences.
The frequency of mutations was similar to other reported cases
of somatic hypermutations found in Rho/TTF, MYC and BCL6
in large-cell lymphomas (MF was from 0.12 for MYC to 0.69 for
Figure 2. Flow chart showing accumulation of mutations
(including two founder mutations) in RASSF1A exons 3–5 in
the single cell clone #9. Synonymous mutation Pro122Pro was
caused by nucleotide change ATCRAAC. Mutation GTCRGTA also
didn’t result in any amino acid change (Val174Val).
doi:10.1371/journal.pone.0005231.g002
Table 5. Founder mutations in single cell KRC/Y clones.
Cell clone Mutation
Number of sequenced
plasmid clones with
founder mutation
All 15 clones nt26.735(ARG) 46
1 T196T 3
2 R240R, K241R 2
3 D157N 4
4 I139T 5
4 V225A 4
5 N155S 3
8 K232R 3
9 I139N 3
9 I146N 2
10 L256W, P274P 2
12 E126G 2
14 L260S 4
15 D262G 3
Total founder mutations 86
doi:10.1371/journal.pone.0005231.t005
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PLoS ONE | www.plosone.org 6 May 2009 | Volume 4 | Issue 5 | e5231Figure 3. Distribution of mutations in RASSF1A (A) and RBSP3 (B and C). For RASSF1A all mutations were analyzed. For RBSP3 mutations found
in GIT (B) and in human cancer (C) were analyzed separately. Bubble graphs depict the proportion of substitutions occurring at each of the four bases
in the RASSF1A and RBSP3, depending on the distance from the mutated nucleotide (No. 0). N, any nucleotide;B=C, G or T; D=A, G or T; S=G or C;
V=A,C, or G; W=A or T.
doi:10.1371/journal.pone.0005231.g003
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ulin genes (12.7 mutations per 100 bp, see [25]. However, for the
first time we found high frequency of somatic mutations in
different tissues including non-haematopoietic and in tumor
suppressor genes contrary to the previous reports where oncogenes
were studied.
As AccuPrime
TMPfx DNA polymerase creates maximally one
error in 3610
6 bp, our results proved that the observed
Figure 4. Reduced growth inhibiting activity of RASSF1A (A) and RBSP3A (B) mutants. A. Growth of stably transformed KRC/Y RCC cells with
wild type and mutant RASSF1A (Cys65Arg and Val211Ala) without doxycycline (the gene is on) is presented in A. On day 6, the number of cells with
wt RASSF1A was 3610
5 and the number of cells with mutant RASSF1A was 5610
5 (1.7 times more than wt). On day 10, the number of cells with wt
RASSF1A was 6610
5 and the number of cells with mutant RASSF1A was 1.8610
6 (3 times more than wt). The effect of expression of wild type and
mutant RBSP3A and RBSP3B on colony formation efficiency in KRC/Y cells is shown in B. Mutants were isolated from the N417 SCLC cell line
(His139Tyr), the ovarian tumor biopsy T4 (three mutations: Asn31Asp, Pro79Ser and Glu87Lys) and the KRC/Y cell line (three mutations: Lys35Met,
Asp103Gly and Leu181Pro). The number of blasticidin-resistant colonies compared to the empty pETE were: 90% for mutant from N417, 15% for
mutant from T4 biopsy and 25% for mutant from KRC/Y. The number of colonies for wtRBSP3A were 5–10% compared to the pETE colonies.
doi:10.1371/journal.pone.0005231.g004
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explained by erroneous performance of polymerases. In our
experiment with SCID mice when AccuPrime
TMPfx DNA
polymerase and 25 cycles were used, 85% of RBSP3 clones
contained mutations.
During the growth of the same cell lines in vitro, 30% of RBSP3
clones (also 25 cycles and AccuPrime
TMPfx DNA polymerase)
were mutant.
In experiments with RASSF1A (391 bp of the first and second
exons), 65% of clones contained mutations (experiments with
normal cells are not included). Moreover, in our experiments, we
used different polymerases with different error rate (see M/M) and
no significant differences in mutation frequency were observed,
arguing against the generation of the mutations during PCR
amplification. Different mutation frequencies between in vivo and
in vitro experiments and in ESTs isolated from normal and cancer
cells is an additional argument against the artificial nature of the
hypermutation rate observed in RBSP3 and RASSF1 genes.
Mutations were detected with similar frequency both in cDNA
and genomic DNA for RBSP3 and RASSF1, however, no high
mutability either on genomic or cDNA level were found for
albumin, insulin, GPR14, TSG p16/INK4a or transcription
elongation factor A (SII) TCEA1. Moreover, no mutations were
found in experiments with SCID mice for 5 genes: BLU, 101F6,
PL6, mutFUS1 and mutP53. Expression of RBSP3 [10] in six tested
samples differed almost 50-fold and on genomic level RBSP3 was
present usually in 3–8 copies [26]. Our previous experiments using
marker NL3-001 located 90 kb apart from the RASSF1A
demonstrated that in tumor cells this region in most cases is
present in 1–5 copies [4,5]. Still the frequency of mutations was
almost the same. Thus number of template molecules didn’t
influence significantly mutability level. Moreover, repeated
sequencing of the same plasmid and isolated by different persons
and at different time gave identical results (6 RASSF1A and 6
RBSP3 plasmid clones were sequenced) excluding frequent
sequencing errors.
Both genes are CG rich however it seems that although high
CG content can induce additional mutations it cannot explain the
fact that two genes with significantly different CG content
(RASSF1A, exons 1–2, 72.3%; RASSF1A, exons 1–6, 59.8% and
RBSP3, exons 1–8, 54.3%) both possess high mutability while
other genes with similar CG content (e.g. GPR14, 72.5%; p16/
INK4a, 71.6%; insulin 61.6%) didn’t show any high frequency of
mutations.
Using the same PCR conditions plasmids containing RBSP3 and
RASSF1A were amplified from E.coli and no mutations were
discovered arguing against generation of mutations during PCR
amplification.
Experiments to find founder mutations with single-cell clones
additionally confirm that mutations originate in the cell.
Interestingly that from the single cell clone No. 9 we isolated
plasmids with one, two or three mutations. This fact clearly
showed how these mutations originate from one parental cell clone
(Figure 2). Importantly after sequencing exons 3–5 of RASSF1A
gene from KRC/Y we discovered founder mutation (destroying
splice acceptor site) that was present in approximately 50% of 98
sequenced plasmid clones. This founder mutation appeared in all
single cell clones and thus most likely it originated before we
started this experiment.
For identification of tumor suppressor genes, we use the gene
inactivation test, GIT [26,27]. This test is based on the functional
inactivation of the analyzed genes during tumor growth in SCID
mice. Our hypothesis was that under selective pressure in vivo the
introduced TSG must be inactivated in growing experimental
(xenografted) tumors (by deletion, mutation, promoter methyla-
tion) as in the naturally growing tumors. The expression of the
tested gene in the GIT was regulated by tetracycline and the level
of expression was under physiological conditions. In our published
papers [10,23] wild type RBSP3 and wild type and mutated
RASSF1A genes were tested in GIT. The genes were PCR
amplified from tumors and sequenced. In contrast to the wild type
RBSP3 and RASSF1 genes, that were inactivated (i.e. deleted, non-
expressed, mutated) in all 32 grown tumors, the mutant RASSF1A
was not additionally mutated in any of four analyzed tumors.
Importantly, in these GIT experiments we used direct sequencing
of PCR products. These experiments showed that ‘‘founding
mutations’’ really do exist.
Analysis of public EST databases confirmed our experimental
data. It should be noted that the frequency of mutations in
RASSF1A and RBSP3 found in EST databases even using very
stringent criteria was significantly higher than found in our
experiments. MF for all mutations for RBSP3 was 0.63 and for
RASSF1 it was 0.22. Probably, this discrepancy could account for
the differences between the cell types analyzed in our experiments
and in the EST database.
Unfortunately only 17 RASSF1A clones could be analysed
because other EST sequences were either not sufficiently good or
could be other isoforms of the RASSF1 gene.
Interestingly, mutations of RASSF1A and RBSP3 changing
amino acids were found even in clones isolated from normal cell
RNA, however, at a lower frequency than in cancer cells (MF
ratios for cancer/normal sequences were 3.3 and 3, respectively).
This difference for both genes was statistically significant
(P,0.001) This probably reflects the selection for and the
advantage of coding mutations during cancer progression.
Important to mention that ‘‘normal’’ sequences include also
non-annotated sequences so we cannot exclude that some of the
‘‘normal’’ sequences actually represent cancer cells.
In fact, these results correlate with the data from the mouse in
vivo experiments that showed a higher frequency of mutations in
SCID tumors than in the same cells grown in vitro. Interestingly,
the same mutations were observed in cells grown in vitro and in vivo,
in SCID mice (see Table S2B).
We have also experimentally tested whether RASSF1A (genomic
DNA, exons1 and 2) harbored mutations in normal tissues and
found one mutated clone out of 14 in normal kidney (normal
control to T356, see section ‘‘Frequent mutations in RASSF1A in
human carcinomas’’). Important to note that so called ‘‘normal’’
kidney could be already partially transformed despite of normal
phenotype because it was obtained from tissues adjacent to the
tumor. We also sequenced complete RASSF1A cDNA from normal
heart and detected six mutated clones out of 15 tested. All six heart
mutated clones contained the same two mutations: L214L with
codon changed from CTA to CTG and V236V with codon
changed from GTA to GTG. Mutations in heart RASSF1 cDNA
were most likely SNP as they could be also found in other RASSF1
clones in public databases (e.g. AC002481, NM_170713.2,
NM_170714.1). In any case it is clear that mutations in RASSF1
in normal cells are more rare than in cancer cells.
As we found mutations in all 5 coding exons of RASSF1A (the
last 6
th exon contains only 48 amino acids=144 bp). It means that
other six known isoforms of RASSF1 are also frequently mutated.
Exceptionally high level of germ line SNP mutations in
RASSF1A found in several studies [8] support our data that the
two genes we studied have rather frequent mutations even in
normal cells.
The pattern of mutations was very different compared to those
reported for AID and APOBEC enzymes and cannot be explained
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frequencies of RASSF1 and RBSP3 genes in different epithelial
malignancies. In our preliminary paper [28] we analyzed
mutations in RASSF1A gene in NPC samples and the results
supported the present observations. In the NPC experiments 35
mutations were detected in 23 patients and mutations were
considered real if at least two clones from the same patient
contained the same mutation. Ten clones for each sample were
sequenced in these experiments. Both DNA strands were
sequenced.
At present, we don’t know the nature of the mechanism
responsible for this hypermutability, and only speculations could
be done for its physiological function(s) in normal cells. There are
several DNA polymerases in vertebrate cells that inaccurately copy
templates and could be involved in generating hypermutations [29].
One of them, POLH (error rate 3610
22), has a mutation target
motif WA and may contribute to hypermutagenesis of immuno-
globulin genes at A-T bases [30]. POLH is expressed in all tissues
and, in principle, could cause hypermutations in non-haematopoi-
etic cells. We found that 50% of all observed mutations in RBSP3
happened in A or T surrounded by G or C. That means that the
mutation target motif for 50% of mutations in RBSP3 is SWS and is
different from the POLH motif. It is reasonable to suggest that
other(s) yet unknown DNApolymerase(s) may be responsible for the
high mutability rates we report here and more than one polymerase
contributes to hypermutations [29,31].
Our results also argue that mutations are not completely random.
Theyarenotcorrelated with predicted numbers (Tables 1,2,3).For
example according to statistical calculations our sequences of
RASSF1A exons 1 and 2 should contain 0.026 nonsense mutations
butinrealitywedetected 3nonsensemutations,P,0.001(seeTable
S1A). For RASSF1A exons 3–5 the predicted number of nonsense
mutations is 0.037 and we found 3 such mutations, P,0.001 (see
Table S1B). This fact may reflect the nature of cancers and normal
tissues studied here. We cannot also exclude that these mutations
still have some preferable motif(s).
We mentioned in the text that clonal selection for more
aggressive growth of cancer cells could add to changing proportion
of different mutations. In our previous paper [28] we also observed
an unusual distribution of mutations. Among 35 detected
mutations we found 30 transitions, 3 transversions, 2 deletions
(frameshift), 3 nonsense (stop), 26 missense and only 4 were
synonymous.
High frequency of mutations in different cancers and normal
cells was reported earlier for P53 [32]. However, at present it is
difficult to compare these results with our study as different
methodologies were used and most likely different mechanisms of
mutagenesis were involved.
When this manuscript was completed two new publications
appeared in PNAS that support our observations and concept
[33,34].
Interestingly, in the paper of Yang et al. [35] hypermutability
was demonstrated in damaged single-strand DNA formed at
double–strand breaks in yeast S. cerevisia. Although yeast data may
not apply to human cells, it is worthwhile to note that AP20 and
LUCA regions where RASSF1 and RBSP3 are located were found
extensively damaged (deletions, amplifications) in 90% of studied
major epithelial cancers [2, 4, 5, see Introduction].
Materials and Methods
Ethics Statement
All work with mice was performed in special ‘‘Animal House’’ in
MTC according to the standard rules. The study was done in
accordance to the guidelines (incl. husbandry) issued by the
STOCKHOLMS Norra Djurforsoksetiska Namnd (Animal Ethic
Committee of North Stockholm).
Paired tumor/normal samples were obtained from the Blokhin
Cancer Research Center, Russian Academy of Medical Sciences
after surgical resection of primary tumors and stored in liquid
nitrogen.. Top and bottom sections (3–5 mm thick) cut from frozen
tumor tissues were examined histologically and only samples
containing 70% or more tumor cells were used in the study. The
samples were collected in accordance to the guidelines issued by
the Ethic Committee of the Blokhin Cancer Research Center,
Russian Academy of Medical Sciences (Moscow). All patients gave
written informed consent that is available upon request. The study
was done in accordance with the principles outlined in the
Declaration of Helsinki.
Cell lines and experiments with SCID mice
Cell lines were obtained from the MTC-KI (Stockholm,
Sweden) cell lines collection. Cell and tumor growth assays were
done as described previously [13,16,23,26]. GIT was performed as
described previous [16,26,27].
In brief, plasmid DNAs were purified using R.E.A.L. Prep kit
(Qiagen, Valencia, CA). Transfections were performed using
LipofectAMINE PLUS Reagent (Life Technologies, Rockville,
MD) according to the manufacturer’s protocol. After transfection,
cells were selected with 5 mg/ml Blasticidin and 200 ng/ml
doxycycline for two-four weeks. For colony formation assay cells
were selected for 2 weeks, fixed, stained with Giemza and counted
for transfection efficiency. For isolation of stably transfected cell
clones, selection was done for four weeks. PCR positive clones
from each recombinant were tested for expression using Northern
hybridization and selected clones, 5610
6 cells/mouse, were
inoculated subcutaneously with or without Matrigel (BD, Franklin
Lakes, NJ) into six-week-old female SCID mice. Each mouse
received only 1 injection. SCID mice were observed for tumor
formation twice a week for up to seven weeks, if tumor formation
was observed, tumors were measured using calipers. The tumors
were explanted for DNA preparations.
General methods
All molecular biology and microbiology procedures were
performed as described previously [10,13,36]. DNA and RNA
were isolated from total tumor samples containing less than 30%
of non-tumor cells according to histopathology examination.
Construction of pETE vector and KRC/Y and LNCaP cell
lines producing tetracycline trans-activator tTA were described in
ref. [26].
Polymerases used for PCR
In experiments with cell lines and biopsies we used natural Taq
polymerase (New Englands Biolabs, Ipswich, MA, USA) and
JumpStart
TMAccuTaqLA DNA Polymerase (Sigma-Aldrich, St.
Louis, MO, USA). In some experiments (for comparison) we used
AccuPrime
TMPfx DNA polymerase (Invitrogen, Carlsbad, CA,
USA). No significant difference was observed between these three
polymerases. Usually 30 cycles were used.
In experiments with single cell clones and SCID mice
AccuPrime
TMPfx DNA polymerase and 25 cycles were employed.
Natural Taq polymerase has an error rate 4.5–5610
25 (i.e.
maximally 1 mistake per 200.000 bp) and the JumpStart
TMAccu-
TaqLA DNA Polymerase exhibits 6.5 fold higher fidelity. In many
experiments, to exclude the possibility of generating mutations
during the polymerization, we used the most error free polymerase
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AccuPrime
TMPfx DNA polymerase and only 25 cycles.
The size of the RBSP3B is 1003 bp and the accuracy of ordinary
Taq polymerase is approximately one error in 2610
5 bp. This
means that after 30 cycles 15% of clones would be expected to
contain mutation(s) in the RBSP3 and after 25 cycles 12.5%. In the
case of AccuPrime
TMPfx DNA polymerase, after 30 cycles 1% of
clones would be mutant and after 25 cycles only 0.84%. In our
experiment with SCID mice, 85% of RBSP3 clones contained
mutations (AccuPrime
TMPfx DNA polymerase, 25 cycles).
During the growth of the same cell lines in vitro, 30% of RBSP3
clones (also 25 cycles and AccuPrime
TMPfx DNA polymerase)
were mutant.
PCR and Sequencing
PCR primers were purchased from Invitrogen (Carlsbad, CA,
USA). PCR was done as described earlier [2]. Initial denaturation
was done for 2 min at 95uC following 25–30 cycles: 95uC for
15 sec, 64uC for 30 sec and extension at 68uC for 1 min per 1 kb.
RBSP3A and RBSP3B: gene fragments (ORF) have been
obtained by PCR from cDNA isolated from different cell lines
using the following primer sets, according to manufacturer’s
manual.
RBSP3B. 120C: 59-GCGGCCGCCGCGCCGCGCACC-
CATGGACGGCCCGGCCATC-39 (nucleotides 1-40) and
HYA22C: 59-AAAACAAAACAGGTAGGCATGGCCA-
CATTC-39 (nucleotides 1003-973). See GenBank Accession
No. AJ575645
RASSF1A: genomic fragments (GenBank Accession
No. AC002481).
Ex1–Ex2. F2A: 59-GCCCAAAGCCAGCGAAGCAC-39 (nu-
cleotides 18051-18070) and EX2F2: 59-ACCCAGG-
CAGCCCTCGAGAA-39 (nucleotides 21066- 21047).
Ex3–Ex5. RassF1-2intrF: 59-TGT CCA TGC TGG CCC ATC
TTG C-39 (nucleotides 26713-26734) and RassF1-5exR: 59-CAC
CTC CCC AGA GTC ATT TTC CTT C-39 (nucleotides 27530-
27554).
RASSF1A: cDNA fragment cDNA (ORF):
F2A: 59-GCCCAAAGCCAGCGAAGCAC-39 (nucleotides 97-
116) and
F2B: 59-AGCCATACCT GGCTACACCCACAGG-39 (nucle-
otides 1343- 1319),
see GenBank Accession No. NM_007182
GPR14: genomic fragment (ORF).
GPR14F: 59 - CCCATCTCAGGGAGTGTCCA - 39 (nucle-
otides -52 - 33),
and GPR14R: 59 - GTAGTTCCTGGTGAGCAGCGTG-
TAG - 39 (nucleotides 966 - 942), see GenBank Accession
No. NM_018949
TCEA1P2: genomic fragment (ORF).
TCEA1F: 59 - TTTGTGAGGAAGGGGGCCTA - 39 (nucle-
otides 705 - 724),
and TCEA1R: 59 - ATATTTTGCCAATTCTTCCAACT-
CAACA - 39 (nucleotides 1775 - 1748), see GenBank Accession
No. X73534
pETE primers [26]:
LiTetF: 59 - GCCTATATAAGCAGAGCTCGTTTAG - 39
AtetR: 59 - CCAAACTCATCAATGTATCTTATCA - 39
Insulin: genomic fragment (ex1–ex3).
InsF: 59-CTGTCACCCAGATCACTGTCCTTC-39 (nucleo-
tides 546-569) and InsR: 59-GGGCTGCGTCTAGTTGCAG-
TAGTT-39 (nucleotides 1702-1679), see GenBank Accession
No. AY138590.1.
Albumin: cDNA fragment (ex12–ex15). AlbF: 59-GAAC-
CAGTTATGTGTGTTGCATGAGAA-39 (nucleotides 1482 -
1508), and AlbR: 59-CCCACAGAAACTAGAAATCCTC-
TACCG-39 (nucleotides 2181 -2155), see GenBank Accession
No. NM_000477.3.
All experiments were performed using Gene Amp PCR System
9700 (Perkin Elmer, Foster City, CA, USA).
PCR products were cloned, using the TOPO TA cloning kit for
sequencing (Invitrogen). Plasmid DNA was purified using the
R.E.A.L.- Prep kit (Qiagen, Valencia, CA). Sequencing was done
using an ABI 310 Sequencer (Applied Biosystems, Foster City,
CA), according to the manufacturer’s protocol.
Bioinformatics
For RASSF1A only exons 1 and 2 with a total length of 357 bp
(Acc.No. NM_007182) were analyzed. For RBSP3 the longest
isoform B (Acc.No. AJ575645; the total length is 831 bp) was
analyzed. The gene sequences were searched against GenBank
EST division, a collection of expressed sequence tags, or short,
single-pass sequence reads from mRNA (cDNA). The statistically
significant thresholds for the alignment (score) that provided
elimination of alien mRNA sequences was set for RASSF1A at 462
and for RBSP3 at 404. These thresholds were obtained from
expertise estimation to cut off clusters of short and non-significant
homologies to the query sequences. An additional manual
refinement against low quality sequences was performed. Nucle-
otide similarity searches were performed with BLAST 2.2.
In all experiments we always compared a given sequence with
the annotated sequences as shown in previous paragraph.
Probabilities of mutation frequency differences were calculated
using Poisson distribution.
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